Described herein are methods for treating T-cell lymphoma in a subject in need thereof, comprising administering to the subject in need thereof, an ETP compound. Also described herein are pharmaceutical compositions and compositions for use that include such ETP compound.

Provided herein, inter alia, is the synthesis of ETP derivatives. The synthetic methods described herein include converting a ring bridging trisulfide compound of formula ##STR00001##
to a ring bridging disulfide compound of formula ##STR00002##
Also provided herein are compositions comprising thereof.

Provided herein, inter alia, is the synthesis of ETP derivatives. The synthetic methods described herein include converting a ring bridging trisulfide compound of formula ##STR00001##
to a ring bridging disulfide compound of formula ##STR00002##
Also provided herein are compositions comprising thereof.

The present invention relates to a pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof and a use thereof. A pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof according to the present invention can bind specifically to DNAJC3 and PDIA3, which are inhibitory of PERK signaling activation, to prevent the inhibition against PERK signaling. Thus, having an advantage of effectively suppressing or inhibiting tau aggregation, the pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof can not only be used in a pharmaceutical composition capable of fundamentally preventing or treating tauopathies associated with the activation of tau protein, but also can find applications in various studies on the development of therapeutic agents for tauopathies, and the expression or activity inhibition of tau protein.

The present invention relates to a pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof and a use thereof. A pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof according to the present invention can bind specifically to DNAJC3 and PDIA3, which are inhibitory of PERK signaling activation, to prevent the inhibition against PERK signaling. Thus, having an advantage of effectively suppressing or inhibiting tau aggregation, the pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof can not only be used in a pharmaceutical composition capable of fundamentally preventing or treating tauopathies associated with the activation of tau protein, but also can find applications in various studies on the development of therapeutic agents for tauopathies, and the expression or activity inhibition of tau protein.

The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.

##STR00001##

The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.

##STR00001##

Compounds of Formula (I):

##STR00001## wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description.

Compounds of Formula (I):

##STR00001## wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description.

The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

##STR00001##